Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abciximab vs Bivalirudin in NSTEMI (ISAR-REACT-4)
NCT00373451Phase 4Completed
- Sponsor
- Deutsches Herzzentrum München
- Start
- Jul 2006
- Primary completion
- May 2011
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of abciximab in non-ST segment elevation myocardial infarction (NSTEMI) (2 arms), sponsored by Deutsches Herzzentrum München. Primary endpoint: Composite of death, large recurrent myocardial infarction (MI), urgent target vessel revascularization (TVR) or major bleeding at 30 days. Started Jul 2006; status: completed.
02
Drugs
abciximab
03
Conditions
non-ST segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on NCT00373451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00373451.